The deal is J&J's biggest move into surgical robotics, which "has been a gap for its medical device business."
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
Deal-makers often don’t consider customers, according to a global branding consultancy. When they do, everybody wins.
The TCJA may force some U.S. companies to reconsider their strategy of shifting profits to affiliates in low-tax jurisdictions.
Johnson & Johnson, Heidrick & Struggles, Amblin Partners, Bruker, Computer Services, Rogers, Outfront Media, LGS Innovations, True Temper Sports
The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.
Amazon's dominance in a growing array of marketplaces could have catastrophic effects.
The chief executives of two health-care giants want the industry to move further toward payments based on quality of care.
Participants and the CFOs who send them to the program express passion for the development of future finance leaders.
Five top finance chiefs tell how they got where they are, and what their potential successors need to do.
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
